Autocrine interleukin-1β production in leukemia: Evidence for the involvement of mutated RAS

Cancer Research

Volumn 59, Issue 12, 1999, Pages 2971-2980

  Beaupre, Darrin M ^a   Talpaz, Moshe ^a   Marini III, Frank C ^a   Cristiano, Richard J ^a   Roth, Jack A ^a   Estrov, Zeev ^a   Albitar, Maher ^a   Freedman, Melvin H ^b   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; ANTIINFLAMMATORY AGENT; ANTISENSE OLIGONUCLEOTIDE; CCAAT ENHANCER BINDING PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOHEXIMIDE; DEXAMETHASONE; DNA BINDING PROTEIN; ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE; INTERLEUKIN 1; MESSENGER RNA; NUCLEAR PROTEIN; PROTEIN SYNTHESIS INHIBITOR; TERPENE; TRANSCRIPTION FACTOR; TRANSFERASE;

ARTICLE; AUTOCRINE EFFECT; CONTROLLED STUDY; GENE ACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOREGULATION; LEUKEMIA; ONCOGENE K RAS; ONCOGENE N RAS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN SECRETION; BIOSYNTHESIS; CELL CULTURE; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; GENE AMPLIFICATION; GENE EXPRESSION; GENE REARRANGEMENT; GENETICS; INFANT; METABOLISM; MUTATION; ONCOGENE RAS; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SOUTHERN BLOTTING;

ALKYL AND ARYL TRANSFERASES; ANTI-INFLAMMATORY AGENTS; AUTOCRINE COMMUNICATION; BLOTTING, SOUTHERN; CCAAT-ENHANCER-BINDING PROTEINS; CELL DIVISION; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLOHEXIMIDE; DEXAMETHASONE; DNA-BINDING PROTEINS; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; GENE AMPLIFICATION; GENE EXPRESSION; GENE REARRANGEMENT; GENES, RAS; HUMANS; INFANT; INTERLEUKIN-1; LEUKEMIA; MUTATION; NUCLEAR PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PROMOTER REGIONS (GENETICS); PROTEIN SYNTHESIS INHIBITORS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TERPENES; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0033563322     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Attias, D., Grunberger, T., Vanek, W., Estrov, Z., Cohen, A., Lau, R., and Freedman, M. H. B-lineage lymphoid blast crisis in juvenile chronic myelogenous leukemia: interleukin-1-mediated autocrine growth regulation of the lymphoblasts. Leukemia (Baltimore), 9: 884-888, 1995.
2. Bagby, G. C., Dinarello, C. A., Neerhout, R. C., Ridgway, D., and McCall, E. Interleukin 1-dependent paracrine granulopoiesis in chronic granulocytic leukemia of the juvenile type. J. Clin. Investig., 82: 1430-1436, 1988.
3. Cohen, A., Grunberger, T., Vanek, W., Dube, I. D., Doherty, P. J., Letarte, M., Roifman, C., and Freedman, M. H. Constitutive expression and role in growth regulation of interleukin-1 and multiple cytokine receptors in a biphenotypic leukemic cell line. Blood, 78: 94-102, 1991.
4. Cozzolino, F., Rubartelli, A., Aldinucci, D., Sitia, R., Torcia, M., Shaw, A., and DiGuglielmo, R. Interleukin 1 as an autocrine growth factor for acute myeloid leukemia cells. Proc. Natl. Acad. Sci. USA, 86: 2369-2373, 1989.
5. Dinarello, C. A. Biologic basis for interleukin-1 in disease. Blood, 87: 2095-2147, 1996.
6. Estrov, Z., Black, R. A., Sleath, P. R., Harris, D., Van, Q., LaPushin, R., Estey, E. H., and Talpaz, M. Effect of interleukin-1β converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation. Blood, 86: 4594-4602, 1995.
7. Estrov, Z., Kurzrock, R., Estey, E., Wetzler, M., Ferrajoli, A., Harris, D., Blake, M., Gutterman, J. U., and Talpaz, M. Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-I receptors. Blood, 79: 1938-1945, 1992.
8. Estrov, Z., Kurzrock, R., Wetzler, M., Kantarjian, H., Blake, M., Harris, D., Gutterman, J. U., and Talpaz, M. Suppression of chronic myelogenous leukemia colony growth by intetleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity. Blood, 78: 1476-1484, 1991.
9. Oster, W., Cicco, N. A., Klein, H., Hirano, T., Kishimoto, T., Lindemann, A., Mertelsmann, R. H., and Hermann, F. Participation of the cytokines interleukin 6, tumor necrosis factor-α, and interleukin 1β secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control. J. Clin. Investig., 84: 451-457, 1989.
10. Rambaldi, A., Torcia, M., Bettoni, S., Vannier, E., Barbui, T., Shaw, A. R., Dinarello, C. A., and Cozzolino, F. Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by interleukin-1 receptor antagonist and lack of its expression by leukemic cells. Blood, 78: 3248-3253, 1991.
11. Sakai, K., Hattori, T., Matsuoka, M., Asou, N., Yamamoto, S., Sagawa, K., and Takatsuki, K. Autocrine stimulation of interleukin-1β in acute myelogenous leukemia cells. J. Exp. Med., 166: 1597-1602, 1987.
12. Schiro, R., Longoni, D., Rossi, V., Maglia, O., Doni, A., Arsura, M., Carrara, G., Masera, G., Vannier, E., Dinarello, C. A., Rambaldi, A., and Biondi, A. Suppression of juvenile chronic myelogenous leukemia colony growth by interleukin-1 receptor antagonist. Blood, 83: 460-465, 1994.
13. Specchia, G., Liso, V., Capalbo, S., Fazioli, F., Bettoni, S., Bassan, R., Viero, P., Barbui, T., and Rambaldi, A. Constitutive expression of IL-1β, M-CSF, and c-fms during the myeloid blastic phase of chronic myelogenous leukaemia. Br. J. Haematol., 80: 310-316, 1992.
14. Wetzler, M., Kurzrock, R., Lowe, D. G., Kantarjian, H., Gutterman, J. U., and Talpaz, M. Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression. Blood, 78: 2400-2406, 1991.
15. Wetzler, M., Kurzrock, R., Estrov, Z., Kantarjian, H., Gisslinger, H., Underbrink, M. P., and Talpaz, M. Altered levels of interleukin-1β and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates. Blood, 84: 3142-3147, 1994.
16. Trahey, M., and McCormick, F. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science (Washington DC), 238: 542-545, 1987.
17. Ahuja, H. G., Foti, A., Bareli, M., and Cline, M. J. The pattern of mutational involvement of ras genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood, 75: 1684-1690, 1990.
18. Kurzrock, R., Kantarjian, H., Wetzler, M., Estrov, Z., Estey, E., Troutman-Worden, K., Gutterman, J. U., and Talpaz, M. Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage. Exp. Hematol., 21: 80-85, 1993.
19. Auron, P. E., and Webb, A. C. Interleukin-1: a gene expression system regulated at multiple levels. Eur. Cytokine Netw., 5: 573-592, 1994.
20. Gray, J. G., Chandra, G., Clay, W. C., Stinnett, S. W., Haneline, S. A., Lorenz, J. J., Patel, I. R., Wisely, G. B., Furdon, P. J., Taylor, J. D., and Kost, T. A. A CRE/ATF-like site in the upstream regulatory sequence of the human interleukin 1β gene is necessary for the induction in U937 and THP-1 monocytic cell lines. Mol. Cell. Biol., 13: 6678-5689, 1993.
21. Hiscott, J., Marois, J., Garoufalis, J., D'Addario, M., Roulston, A., Kwan, I., Pepin, N., Lacoste, J., Nguyen, H., Bensi, G., and Fenlon, M. Characterization of a functional NF-kB site in the human interleukin 1β promoter: evidence for a positive autoregulatory loop. Mol. Cell. Biol., 13: 6231-6240, 1993.
22. Shirakawa, H., Saito, F. K., Bonagura, C. A., Galson, D. L., Fenton, M. J., Webb, A. C., and Auron, P. E. The human prointerleukin 1β gene requires DNA sequences both proximal and distal to the transcription start site for tissue-specific induction. Mol. Cell. Biol., 13: 1332-1344, 1993.
23. Tsukada, J., Saito, K., Waterman, W. R., Webb, A. C., and Auron, P. E. Transcription factors NF-IL6 and CREB recognize a common essential site in the human prointerleukin 1β gene. Mol. Cell. Biol., 14: 7285-7297, 1994.
24. Demetri, G. D., Ernst, T. J., Pratt, E. S., Zenzie, B. W., Rheinwald, J. G., and Griffin, J. D. Expression of ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine genes. J. Clin. Investig., 86: 1261-1269, 1990.
25. Buscher, D. P., Dello Sbarba, E. R., Stanley, E. R., Rapp, U. R., and Baccarini, M. v-raf confers CSF-1-independent growth to a macrophage cell line and leads to immediate early gene expression without MAP-kinase activation. Oncogene, 8: 3323-3327, 1993.
26. Reimann, T., Buscher, D., Hipskind, R. A., Krautwald, S., Lohmann-Matthes, M. L., and Baccarini, M. Lipopolysaccharide induces activation of the raf-1/MAP kinase pathway: a putative role for raf-1 in the induction of the II-1β and TNF-α genes. J. Immunol., 153: 5740-5749, 1994.
27. Prendergast, G. C., and Gibbs, J. B. Ras regulatory interactions: novel targets for anti-cancer intervention. Bioessays, 16: 187-191, 1993.
28. Okuda, K., Matulonis, U., Salgia, R., Kanakura, Y., Druker, B., and Griffin, J. D. Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1. Exp. Hematol., 22: 1111-1117, 1994.
29. Beaupre, D. M., and Kurzrock, R. RAS and leukemia: from basic mechanisms to gene-directed therapy. J. Clin. Oncol., 17: 1071-1079, 1999.
30. Miyauchi, J., Asada, M., Sasaki, M., Tsunematsu, Y., Kojima, S., and Mizutani, S. Mutations of the N-ras gene in juvenile chronic myelogenous leukemia. Blood, 83: 2248-2254, 1994.
31. Neri, A., Knowles, D. M., Greco, A., McCormick, F., and Dalla-Favera, R. Analysis of ras oncogene mutations in human lymphoid malignancies. Proc. Natl. Acad. Sci. USA, 85: 9268-9272, 1988.
32. Janssen, J. W. G., Steenvoorden, A. C. M., Lyons, J., Anger, B., Bohlke, J. U., Bos, J. L., Seliger, H., and Bartram, C. R. Ras gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes. Proc. Natl. Acad. Sci. USA, 84: 9228-9232, 1987.
33. Urbano-Ispizua, A., Gill, R., Matutes, E., Levi, S., Wiedemann, L. M., Catovsky, D., and Marshall, C. J. Low frequency of ras oncogene mutations in Philadelphia-positive acute leukemia and report of a novel mutation H61 leu in a single case. Leukemia (Baltimore), 6: 342-346, 1992.
34. Pendergast, A. M., Quilliam, L. A., Cripe, L. D., Bassing, C. H., Dai, Z., Li, N., Batzer, A., Rabun, K. M., Der, C. J., Schlessinger, J., and Gishizky, M. L. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell, 75: 175-185, 1993.
35. ras. Blood, 84: 3435-3439, 1994.
36. Shannon, K. M., O'Connell, P., Martin, G. A., Paderanga, D., Olson, K., Dinndorf, P., and McCormick, F. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N. Engl. J. Med., 330: 597-601, 1994.
37. Xu, G. F., Lin, B., Tanaka, K., Dunn, D., Wood, D., Gesteland, R., White, R., Wiess, R., and Tamanoi, F. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell. 63: 835-841, 1990.
38. Bollag, G., Clapp, D. W., Shin, S., Adler, F., Zhang, Y. Y., Thompson, P., Lange, B. J., Freedman, M. H., McCormick, F., Jacks, T., and Shannon, K. Loss of NF1 results in activation of the ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat. Genet., 12: 144-148, 1996.
39. Gibbs, J. B., Marshall, M. S., Scolnick, E. M., Dixon, R. A. F., and Vogel, U. S. Modulation of guanine nucleotides bound to ras in NIH3T3 cells by oncogenes, growth factors, and the GTPase activating protein (GAP). J. Biol. Chem., 265: 20437-20442, 1990.
40. ras-GTP complex in Swiss mouse 3T3 cells. Proc. Natl. Acad. Sci. USA, 87: 5993-5997, 1990.
41. Golub, T. R., Barker, G. F., Lovett, M., and Gilliland, D. G. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell, 77: 307-316, 1994.
42. Lorenz, J. J., Furdon, P. J., Taylor, J. D., Varghese, M. W., Chandra, G., Kost, T. A., Haneline, S. A., Roner, L. A., and Gray, J. G. A cyclic adenosine 3′5′-monophosphate signal is required for the induction of IL-1β by TNF-α in human monocytes. J. Immunol., 155: 836-844, 1995.
43. Clark, B. D., Collins, K. L., Gandy, M. S., Webb, A. C., and Auron, P. E. Genomic sequence for human prointerleukin 1β: possible evolution from a reverse transcribed prointerleukin 1α gene. Nucleic Acids Res., 14: 7897-7914, 1986.
44. Fenton, M. J., Clark, B. D., Collins, K. L., Webb, A. C., Rich, A., and Auron, P. E. Transcriptional regulation of the human prointerleukin 1β gene. J. Immunol., 138: 3972-3979, 1987.
45. Nishida, T., Takano, M., Kawakami, T., Nishino, N., Nakai, S., and Hirai, Y. The transcription of the interleukin 1β gene is induced with PMA and inhibited with dexamethasone in U937 cells. Biochem. Biophys. Res. Commun., 156: 269-274, 1988.
46. Turner, M., Chantry, D., Buchan, G., Barrett, K., and Feldmann, M. Regulation of expression of human IL-1α and IL-1β genes. J. Immunol., 143: 3556-3561, 1989.
47. Weinstein, S. L., Sanghera, J. S., Lemke, K., DeFranco, A. L., and Pelech, S. L. Bacterial lipopolysaccharide induces tyrosine phosphorylation and activation of mitogen-activated protein kinases in macrophages. J. Biol. Chem., 267: 14955-14962, 1992.
48. Nakajima, T., Kinoshita, S., Sasagawa, T., Sasaki, K., Naruto, M., Kishimoto, T., and Akira, S. Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. Proc. Natl. Acad. Sci. USA, 90: 2207-2211, 1993.
49. Xing, J., Ginty, D. D., and Greenberg, M. E. Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science (Washington DC), 273: 959-963, 1996
50. Crowell, P. L., Chang, R. R., Ren, Z., Elson, C. E., and Gould, M. N. Selective inhibition of isoprenylation of 21-26-kDa proteins by the anticarcinogen D-limonene and its metabolites. J. Biol. Chem., 266: 17679-17685, 1991.
51. Garcia, M., Rowell, C., Ackermann, K., Kowalczyk, J. J., and Lewis, M. D. Peptidomimetic inhibitors of ras farnesylation and function in whole cells. J. Biol. Chem., 268: 18415-18418, 1993.
52. Jackson, J. H., Cochrane, C. G., Bourne, J. R., Solski, P. A., Buss, J. E., and C. J., D. Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc. Natl. Acad. Sci. USA, 87: 3042-3046, 1990.
53. ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus. EMBO J., 3: 2581-2585, 1984.
54. Hohl, R. J., and Lewis, K. Differential effects of monoterpenes and lovastatin on ras processing. J. Biol. Chem., 270: 17508-17512, 1995.
55. Crowell, P. L., Ren, Z., Lin, S., Vedejs, E., and Gould, M. N. Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation. Biochem. Pharmacol., 47: 1405-1415, 1994.
56. Alemany, R., Ruan, S., Kataoka, M., Koch, P. E., Mukhopadhyay, T., Cristiano, R. J., Roth, J. A., and Zhang, W. W. Growth inhibitory effect of anti-K-ras adenovirus on lung cancer cells. Cancer Gene Ther., 3: 296-301, 1996.
57. Barinaga, M. Two major signaling pathways meet at MAP-kinase. Science (Washington DC), 269: 1673, 1995.
58. Finco, T. S., and Baldwin, A. S. kB site-dependent induction of gene expression by diverse inducers of nuclear factor kB requires raf-1. J. Biol. Chem., 268: 17676-17679, 1993.
59. Li, S., and Sedivy, J. M. Raf-1 protein kinase activates the NF-kB transcription factor by dissociating the cytoplasmic NF-kB-IkB complex. Proc. Natl. Acad. Sci. USA, 90: 9247-9251, 1993.
60. Tamanoi, F. Inhibitors of ras farnesyltransferases. Trends Biochem. Sci., 18: 349-353, 1993.
61. Tsuchiya, S., Yamabe, M., Yamaguchi, Y., Kobayashi, Y., Konno, T., and Tada, K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int. J. Cancer, 26: 171-176, 1980.
62. Baldari, C., Murray, J. A. H., Ghiara, P., Cesareni, G., and Galeotti, C. L. A novel leader peptide which allows efficient secretion of a fragment of human interleukin 1β in Saccharomyces cerevisiae. EMBO J., 6: 229-234, 1987.
63. Adams, M. D., Kelley, J. M., Gocayne, J. D., Dubnick, M., Polymeropoulos, M. H., Xiao, H., Merril, C. R., Wu, A., Olde, B., Moreno, R. F., Kerlavage, A. R., McCombie, W. R., and Venter, J. C. Complementary DNA sequencing: expressed sequence tags and the human genome project. Science (Washington DC), 252: 1651-1656, 1991.
64. Thomas, P. S. Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose. Proc. Natl. Acad. Sci. USA, 77: 5201-5203, 1980.
65. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. Current Protocols in Molecular Biology. New York: Greene Publishing Associates and Wiley Interscience, 1991.
66. Southern, E. M. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J. Mol. Biol., 98: 503-505, 1975.
67. Newell, C. L., Deisseroth, A. B., and Lopez-Berestein, G. Interaction of nuclear proteins with an AP-1/CRE-like promoter sequence in the human TNF-α gene. J. Leukoc. Biol., 56: 27-35, 1994.
68. Mukhopadhyay, T., Tainsky, M., Cavender, A. C., and Roth, J. A. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res., 51: 1744-1748, 1991.
69. Gelb, M. H., Scholten, J. D., and Sebolt-Leopold, J. S. Protein prenylation: from discovery to prospects for cancer treatment. Curr. Opin. Chem. Biol., 2: 40-48, 1998.
70. Yang, W., Del Villar, K., Urano, J., Mitsuzawa, H., and Tamanoi, F. Advances in the development of farnesyltransferase inhibitors: substrate recognition by protein fame-syltransferase. J. Cell. Biochem., 27: 12-19, 1997.
71. Castelli, C., Sensi, M., Lupetti, R., Mortarini, R., Panceri, P., Anichini, A., and Parmiani, G. Expression of interleukin 1α, interleukin 6, and tumor necrosis factor α genes in human melanoma clones is associated with that of mutated N-RAS oncogene. Cancer Res., 54: 4785-4790, 1994.